SPP1 and myeloid sarcoma: Despite these alterations in the OPN levels between different MS subtypes, the meta-analysis did not find any difference in the CSF OPN levels of MS patients and patients with other inflammatory neurological diseases [204] No other comparison between MS subtypes has shown a significant difference in blood and/or CSF OPN levels between the examined groups.